Innate lymphoid cells (ILCs) are a heterogeneous group of mucosal inflammatory cells that participate in chronic intestinal inflammation. We investigated the role of interleukin 6 (IL6) in inducing activation of ILCs in mice and in human beings with chronic intestinal inflammation. METHODS: ILCs were isolated from colons of Tbx21 -/-Â Rag2 -/-mice (TRUC), which develop colitis; patients with inflammatory bowel disease (IBD); and patients without colon inflammation (controls). ILCs were characterized by flow cytometry; cytokine production was measured by enzymelinked immunosorbent assay and cytokine bead arrays. Mice were given intraperitoneal injections of depleting (CD4, CD90), neutralizing (IL6), or control antibodies. Isolated colon tissues were analyzed by histology, explant organ culture, and cell culture. Bacterial DNA was extracted from mouse fecal samples to assess the intestinal microbiota. RESULTS: IL17A-and IL22-producing, natural cytotoxicity receptor-negative, ILC3 were the major subset of ILCs detected in colons of TRUC mice. Combinations of IL23 and IL1a induced production of cytokines by these cells, which increased further after administration of IL6. Antibodies against IL6 reduced colitis in TRUC mice without significantly affecting the structure of their intestinal microbiota. Addition of IL6 increased production of IL17A, IL22, and interferon-g by human intestinal CD3-negative, IL7-receptor-positive cells, in a dose-dependent manner. CON-CLUSIONS: IL6 contributes to activation of colonic natural cytotoxicity receptor-negative, CD4-negative, ILC3s in mice with chronic intestinal inflammation (TRUC mice) by increasing IL23-and IL1a-induced production of IL17A and IL22. This pathway might be targeted to treat patients with IBD because IL6, which is highly produced in colonic tissue by some IBD patients, also increased the production of IL17A, IL22, and interferon-g by cultured human colon CD3-negative, IL7-receptor-positive cells.
BACKGROUND & AIMS:
Innate lymphoid cells (ILCs) are a heterogeneous group of mucosal inflammatory cells that participate in chronic intestinal inflammation. We investigated the role of interleukin 6 (IL6) in inducing activation of ILCs in mice and in human beings with chronic intestinal inflammation.
METHODS: ILCs were isolated from colons of Tbx21
-/-Â Rag2 -/-mice (TRUC), which develop colitis; patients with inflammatory bowel disease (IBD); and patients without colon inflammation (controls). ILCs were characterized by flow cytometry; cytokine production was measured by enzymelinked immunosorbent assay and cytokine bead arrays. Mice were given intraperitoneal injections of depleting (CD4, CD90), neutralizing (IL6), or control antibodies. Isolated colon tissues were analyzed by histology, explant organ culture, and cell culture. Bacterial DNA was extracted from mouse fecal samples to assess the intestinal microbiota. RESULTS: IL17A-and IL22-producing, natural cytotoxicity receptor-negative, ILC3 were the major subset of ILCs detected in colons of TRUC mice. Combinations of IL23 and IL1a induced production of cytokines by these cells, which increased further after administration of IL6. Antibodies against IL6 reduced colitis in TRUC mice without significantly affecting the structure of their intestinal microbiota. Addition of IL6 increased production of IL17A, IL22, and interferon-g by human intestinal CD3-negative, IL7-receptor-positive cells, in a dose-dependent manner. CON-CLUSIONS: IL6 contributes to activation of colonic natural cytotoxicity receptor-negative, CD4-negative, ILC3s in mice with chronic intestinal inflammation (TRUC mice) by increasing IL23-and IL1a-induced production of IL17A and IL22. This pathway might be targeted to treat patients with IBD because IL6, which is highly produced in colonic tissue by some IBD patients, also increased the production of IL17A, IL22, and interferon-g by cultured human colon CD3-negative, IL7-receptor-positive cells.
Keywords: UC; CD; Innate Immunity; Immune Regulation. I nflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is an increasingly common immune-mediated disease of the gut of unknown cause. 1, 2 The genetic architecture of IBD is complex, with more than 130 significantly associated susceptibility loci identified to date, 3 indicating that multiple mechanisms of disease may exist. Nevertheless, prominent roles for innate immunity and particular immune response pathways, including the interleukin (IL) 23/IL17 axis, strongly are implicated.
Innate lymphoid cells (ILCs) are emerging as important players in mucosal immunity. Although recognized to perform protective roles against mucosal pathogens, 4,5 they also contribute to chronic intestinal inflammation, which is particularly apparent in mice lacking conventional T and B cells. 6, 7 This is in part dependent on their capacity to produce inflammatory cytokines, including interferon-g, IL17A, and IL22. [4] [5] [6] [7] [8] ILCs can be subdivided into discrete populations, which accumulate in mucosal tissues in different pathologic settings. 9 At least 3 subsets exist, including ILC1s, which produce interferon-g; ILC2s, which produce IL5/ IL13; and ILC3, which can be subdivided further based on differential expression of natural cytotoxicity receptors (NCRs), CD4, and production of IL17 and/or IL22.
Tbx21
-/-Rag2 -/-ulcerative colitis (TRUC) mice spontaneously develop severe colitis with striking similarities to some aspects of human UC. 10 Colon lesions histologically resemble UC with goblet cell depletion, crypt abscess formation, epithelial hyperplasia, and infiltration of colonic lamina propria with neutrophils and mononuclear cells. 7, 10 TRUC mice develop inflammation-associated epithelial dysplasia, which frequently progresses to frank adenocarcinoma, 11 one of the most severe complications in human forms of IBD. TRUC disease is dependent on interactions between intestinal CD11c þ mononuclear phagocytes and CD90 þ IL7R-receptor-positive (IL7R þ ) ILCs. 7 Depletion of ILCs or genetic deficiency of the common g-chain cytokine receptor, which is necessary for ILC survival, prevents disease. 7 Similarly, blockade of IL23 or IL17A significantly attenuates disease. 7 ILCs accumulate in gut lesions from IBD patients [12] [13] [14] and it has been speculated that targeting these cells might represent a viable therapeutic approach in IBD. 15 
IL23
6,7 and IL1b 16 contribute to ILC activation, although curiously TRUC mice that additionally are deficient for either IL23R or IL1R are not fully protected from colitis, 17 consistent with a possible role for alternative ILC activation pathways contributing to disease. The purpose of this study was to investigate the proximal signals responsible for driving intestinal ILC activation and to determine whether similar pathways might exist in human disease.
Materials and Methods

Mice
Balb/C Rag2 -/-and wild-type mice were sourced commercially (Jackson Laboratories; Bar Harbor, ME). TRUC mice were a gift from Laurie Glimcher. Animal experiments were performed in accredited facilities in accordance with the UK Animals (Scientific Procedures) Act 1986 (Home Office License Number PPL: 70/6792 and PPL: 70/7869 from November 2013).
Human Studies
Studies in human tissues received ethical approval from the City and Hackney Local Research Ethics Committee (REC reference: 10/H0704/74 and 10/H0804/65). Colonic lamina propria mononuclear cells (cLPMCs) were isolated as described previously 18 from colectomy specimens and endoscopically acquired biopsy specimens. Normal colonic mucosal samples were collected from macroscopically unaffected areas of patients undergoing intestinal resection for colon cancer or polyps. Informed written consent was obtained in all cases.
Flow Cytometry and Cell Sorting
Intracellular cytokine expression was measured as described previously. 7 Cells were stimulated with IL23 (10-20 ng/mL), IL6 (10-100 ng/mL), or phorbol 12-myristate 13-acetate (PMA) (50 ng/mL) and ionomycin (1 mmol/L) for 4-6 hours at 37 C with monensin (3 mmol/L) added for the last 2 hours. In human work, antibodies used to stain cell surface antigens were incubated with unstimulated cells for 25 minutes and then fixed in 2% paraformaldehyde pending analysis. For fluorescence-activated cell sorter purification of murine
ILCs, CD45
þ cells first were sorted immunomagnetically from unfractionated cLPMCs using anti-CD45 beads (Miltenyi) and LS columns (Miltenyi). CD45 þ cells were stained with CD90, NKp46, and IL7R. Antibodies used in flow cytometry experiments are listed in Supplementary Table 1 .
Ex Vivo Organ Culture
Colon explants cultures from murine experiments were performed as described previously. 7 Three biopsy punches from the distal colon were cultured in 500 mL of complete medium for 24 hours at 37 C. In human studies explant cultures were set up as described previously. 18 Cytokine production in culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA).
Cell Culture
Unfractionated murine splenocytes (2 Â 10 6 /mL) and mesenteric lymph node (mLN) cells (1 Â 10 6 /mL) or cLPMCs (1 Â 10 6 /mL) were cultured in complete medium for 24 hours at 37 C as described previously. 7 cLPMCs from IBD and noninflammatory control patients were cultured with recombinant human IL6 (R&D) (0-100 ng/mL) overnight at 37 C, 5% CO 2 , and then restimulated with PMA (50 ng/mL) and ionomycin (1 mmol/L). In some experiments, cLPMCs were cultured with IL6 (100 ng/mL) for 6 hours in the presence of monensin (3 mmol/L). Fluorescence-activated cell sorter-puri-
) from TRUC mice were cultured at 5 Â 10 4 /mL for 24 hours. Cytokine concentrations in culture supernatants were measured by ELISA (R&D Systems and eBioscience).
Histology
Colon histology was processed, stained (H&E), and colitis scores were calculated as described previously. 7 Proximal and distal colitis scores from individual mice were averaged, unless otherwise stated.
ELISA and Cytokine Bead Arrays
Cytokine concentrations were measured in culture supernatants by ELISA or T-helper cell (Th)1, Th2, or Th17 CBA (BD Biosciences).
Microarray and Real-Time Polymerase Chain Reaction
RNA was extracted from 3 Rag2
-/-and 3 TRUC mice, aged 10 weeks, using TRIzol reagent (Invitrogen Carlsbad, CA). Transcript expression was analyzed with Mouse Genome 430 2.0 Affymetrix Expression Array. For real-time polymerase chain reaction (PCR) experiments cells were lysed in TRIzol reagent (Invitrogen) and RNA was extracted. Complementary DNA was generated with the complementary DNA synthesis kit (Bioline, Taunton, MA). Quantitative PCR was used to quantify messenger RNA transcripts using TaqMan gene expression assays (Applied Biosystems). Gene expression was normalized to the expression of b-actin to generate DCT values and relative abundance was quantified using the 2 -DCT method. Human RORC (Hs01076112_m1) and b-actin (4326315E) TaqMan quantitative PCR primer sets were used. þ cells were present in mLNs of TRUC mice (many of which co-expressed CD90); however, very few CD4
þ cells were present in the colon ( Figure 1C ). Given the low frequency of intestinal CD4
þ ILCs in TRUC mice we considered it unlikely that these cells would play a major role in disease. To test this assumption we depleted CD4-expressing cells in vivo. The administration of anti-CD4 antibodies successfully depleted CD4-expressing cells in mLNs and colon of TRUC mice ( Figure 1C ). However, many CD90 þ cells still remained in the colon and there was no reduction in the number of IL17A-or IL22-producing cells ( Figure 1D ). Depleting anti-CD4 treatment did not alter the severity of TRUC disease significantly ( Figure 1E ). In contrast, anti-CD90 treatment depleted both CD90-and CD4-expressing ILCs, reduced the number of IL17-and IL22-producing cells in the colon, and significantly attenuated disease ( Figure 1C-E) . Taken together, these data indicate IL17A/IL22 producing CD90 þ IL7R þ NCR -CD4 -ILC3 are the key ILC population in the colon responsible for causing disease in TRUC mice.
IL6 Is Expressed Highly and Augments Pathogenic Cytokine Production in TRUC Mice
We sought to define the proximal immune signals responsible for triggering effector function of colonic NCR -ILC3 in TRUC mice. IL1b and IL6 were among the most highly expressed (>2-fold induction) cytokine transcripts in the colon of TRUC mice in comparison with Rag2 -/-mice ( Figure 2A ). The other IL1 family member, Il1a, and the IL23 subunit transcripts (Il23a and Il12b) also were increased. Proximal cytokines responsible for driving ILC1 (IL12, IL15, and IL18) or ILC2 (IL25 and IL33) responses were not up-regulated, and, indeed in most instances were downregulated in the colon of TRUC mice in comparison with Rag2 -/-controls. IL23 and IL1 have been described to play an important role triggering ILCs in TRUC disease, therefore, in this study we focussed our attention on IL6. In addition to increased Il6 transcripts in the colon, there were very high concentrations of IL6 in serum and significantly increased production of IL6 in colon explant cultures from TRUC mice (Supplementary Figure 2A) . Transcripts of genes known to be regulated by IL6 19 were up-regulated in the colon of TRUC mice in comparison with Rag2 -/-controls (Supplementary Figure 2B) , including well-recognized immune genes (Socs1, Socs3, and Icam1), IL6 signaling components (Stat1 and Stat3), and anti-apoptotic genes (Bcl3, Bcl6, and Bcl-x1). The most highly expressed IL6-regulated gene in the colon of TRUC mice (12-fold enrichment) was Pou2af1, which encodes a transcriptional co-activator responsible for IL6-mediated regulation of IL17 responses in T cells. 20 To determine whether IL6 might trigger ILC-derived cytokines we stimulated unfractionated cLPMCs and mLN cells from TRUC mice with recombinant IL6. Strikingly, IL6 triggered IL17A production by both cLPMCs and mLN cells ( Figure 2B ). We also performed flow cytometry with intracellular cytokine staining after IL6 stimulation of unfractionated mLN cells. Although less potent than IL23, IL6 induced expression of IL17A in NCR -ILC3s ( Figure 2C ). To determine whether this was a cell-intrinsic phenomenon we purified CD90 þ IL7R þ NCR -ILC3s from TRUC colons by fluorescence-activated cell sorting (Supplementary Figure 3A) . To our surprise, neither IL6, IL23, nor IL1a by themselves induced significant cytokine production by purified colonic NCR -ILC3s ( Figure 2D ). However, the combination of IL23 and IL1a was a potent trigger for ILC production of IL17A and IL22. The addition of IL6 together with IL23 and IL1a was the most potent trigger of all. Purified intestinal NCR -ILCs from TRUC mice produced little tumor necrosis factor a or interferon-g under these conditions (Supplementary Figure 3B) . IL23 and IL1a were weak inducers of IL6 by colonic NCR -ILCs (Supplementary Figure 3B) . Taken together, these data showed that IL6 augments IL23/IL1a-induced pathogenic cytokine production by intestinal ILCs in TRUC mice in a cell-intrinsic manner.
IL6 signals through a heterodimeric receptor comprising ubiquitously expressed gp130 and selectively expressed IL6Ra. However, IL6Ra also exists as a soluble form, which can complex with IL6 in solution and then bind to cells expressing gp130, enabling cells, which do not usually express IL6Ra, to respond to IL6 stimulation. Therefore, we investigated IL6Ra and soluble IL6Ra (sIL6Ra) expression in TRUC mice. IL6Ra expression by ILCs was highly variable in the colon of TRUC mice, but typically was less than 10% (Supplementary Figure 4A , and data not shown). However, sIL6Ra was abundant in the serum of TRUC mice and was detected in supernatants from cultured colon explants and unfractionated splenocytes (Supplementary Figure 4B) . Therefore, it is likely that ILCs respond to IL6 stimulation directly, but also potentially through trans-signaling given the abundance of sIL6R in TRUC mice. 
IL6 Blockade Attenuated TRUC Disease Independently of Changes to Intestinal Microbiota Community Profiles
To determine whether IL6-mediated activation of innate immunity was functionally important in TRUC disease, mice were treated with monoclonal antibodies that neutralize the biological activity of IL6. Treatment with anti-IL6 resulted in loss of IL6 bioavailability (Supplementary Figure 5A) . IL17A production by unfractionated cLPMCs and splenocytes was reduced significantly in anti-IL6-treated TRUC mice, although was not abolished completely ( Figure 3A ). IL6 neutralization significantly attenuated TRUC disease, including reduced colitis scores and reduced splenomegaly ( Figure 3B and C).
Similar to the situation in human IBD, TRUC disease is associated with perturbation of intestinal microbial communities. Because IL6 directly influences the success of mucosal colonization by some intestinal bacteria, 21 we considered the possibility that attenuation of chronic TRUC disease after IL6 blockade might have occurred secondarily to changes in key components in the composition of the intestinal microbiota. To address this question we sequenced 16S ribosomal RNA genes that were PCRamplified from fecal samples from anti-IL6 or control antibody-treated TRUC mice. Overall, we identified 2642 different operational taxonomic units (OTUs). Treatment with anti-IL6 antibody appeared to have a relatively minor impact on the microbiota ( Figure 4A) . At the phylum level, Firmicutes were reduced slightly in proportional abundance in anti-IL6-treated mice (P ¼ .035) ( Figure 4A ) but, at finer taxonomic levels, anti-IL6 treatment did not impact the proportional abundance of the most common 150 OTUs significantly, which cumulatively accounted for more than 96% of the total amount of sequence data generated (Supplementary Table 2 ). Cluster analysis, using the Bray Curtis calculator, confirmed that there was no signature microbiota profile associated with anti-IL6 treatment (Supplementary Figure 5B) . Helicobacter typhlonius was ubiquitously present in anti-IL6-or isotype control-treated mice, however, the proportional abundance did not differ significantly between the 2 groups either before or after treatment ( Figure 4B ). There was a tendency for increased bacterial diversity in the gut of anti-IL6-treated mice in comparison with control antibody-treated mice, although this did not achieve statistical significance (P < .095) (Supplementary Figure 5C ).
IL6 Augments Pathogenic Cytokine Production by Colonic CD3 -IL7R þ Cells From IBD Patients
Our preclinical data support the possibility that targeting IL6 may be therapeutically tractable in chronic gut inflammation. Therefore, we aimed to verify whether this pathway was relevant in human disease. As expected, stimulation of unfractionated intestinal immune cells with PMA and ionomycin resulted in production of pathogenic cytokines, including IL17A, IL22, and interferon-g by CD3 þ T cells ( Figure 5A and Supplementary Figure 6A) . However, we also observed production of these cytokines in the non-T-cell (CD3 -) fraction, particularly in IBD patients. Within the non-T-cell fraction (CD3 -), we could identify a population of IL7R-expressing cells in the colon of patients with CD, UC, and noninflammatory control patients ( Figure 5B ). Although the frequency of these cells was variable, their proportional abundance within the lymphocyte population was increased in IBD patients in comparison with noninflammatory controls ( Figure 5B ). Consistent with ILC3s being present among the CD3 -IL7R þ population, there was enriched expression of RORgt and c-kit (CD117) ( Figure 5C and Supplementary Figure 6C) . RORC transcripts also were enriched in fluorescence-activated cell sorter-purified CD3 -
IL7R
þ cells analyzed by real-time PCR (Supplementary Figure 6B) 
NKp46
-cells were the predominant subset present ( Figure 5D and Supplementary Figure 6C) .
To determine whether CD3 -IL7R þ cells present in diseased mucosa of IBD patients were responsive to IL6, cLPMCs were incubated overnight with recombinant human IL6 before being restimulated with PMA and ionomycin. Production of IL17A, IL22, and interferon-g by CD3 -IL7R þ cells was increased significantly when cLPMCs were cultured in the presence of IL6 ( Figure 6A and B). In addition, some samples were stimulated with IL6 directly without mitogen, which showed induction of IL17A by CD3 -IL7R þ cells in a dose-dependent manner ( Figure 6C ). Finally, we analyzed IL6 production by diseased mucosa from IBD patients to see whether blocking IL6 might be a reasonable therapeutic strategy in some or all IBD patients. IL6 was produced by colon explant cultures in CD, UC, and noninflammatory control patients (Supplementary Figure 6D) . However, IL6 production was variable, especially in IBD patients, ranging from 72.2 to 8426.4 pg/mg colonic tissue. IBD patients could be stratified according to mucosal production of IL6, with half of IBD patients producing relatively low levels comparable with noninflammatory control patients and the other half producing high amounts (>1000 pg/mg tissue). Taken together, these data indicate that IL6, which is produced in very high quantities in approximately 50% of CD and UC patients drives pathologically relevant immune pathways in chronic intestinal inflammation.
Discussion
CD4
-NCR -ILC3s are the predominant CD90 þ IL7R þ ILC population in the colon of TRUC mice responsible for causing disease. Purified intestinal NCR -ILC3 from TRUC mice produced IL17A and IL22, but were poor producers of interferon-g and tumor necrosis factor a. They were also a modest source of IL6. Few NCR þ ILCs were present in the colon of TRUC mice, consistent with data from other groups reporting a requirement for T-bet in NKp46 þ ILC development and differentiation. 22 Intestinal CD4 þ ILCs are important in host resistance to intestinal pathogens, such as Citrobacter rodentium. 5 Here, we show that CD4 þ ILCs, which are abundant in mLN, but infrequent in the colon, do not play a major role in TRUC disease. Depletion of CD4 þ ILCs had no impact on pathogenic cytokine production or disease outcome.
In TRUC mice, highly purified colonic NCR IL6 is a pleiotropic cytokine that may be important in IBD. Peripheral blood and cLPMCs produce excess IL6 in IBD, 23, 24 often at levels correlating with disease activity.
25
Genetic variation at the IL6 locus is linked with early onset IBD 26 and polymorphisms at loci encoding IL6R signaling components are associated with increased IBD risk.
3 IL6 blockade is therapeutic in some preclinical models of IBD, although it has been assumed that the therapeutic mechanism likely was attributable to limitation of T-cell-mediated pathology [27] [28] [29] [30] because IL6 contributes to intestinal Th17 differentiation. 31 We show a novel role of IL6 in innate immune-mediated chronic intestinal pathology. It is interesting that cytokines contributing to CD4 þ Th17 differentiation, including IL1, IL23, and IL6, have conserved roles promoting innate IL17 production. Our data build on other work implicating ILCs as potentially important mediators in IBD, [12] [13] [14] and confirm NCR -ILC3 as a source of pathogenic cytokines in IBD. Polymorphisms at multiple susceptibility loci in IBD that previously were considered to impact adaptive immunity, similarly could impact ILC phenotype, including RORC, IL23R, IL12RB2, IL12B, IL22, IFNG, STAT1, STAT3, STAT4, CCR6, IL1R1, IL15RA, and IL6ST.
3 Accordingly, it is possible that genetic variation at these loci in IBD could impact disease susceptibility by altering the activation and effector function of mucosal ILCs. However, the relative contribution of ILC to the initiation and propagation of chronic intestinal inflammation in IBD remains to be determined. Polyclonal stimulus of unfractionated cLPMCs from IBD patients showed that most cytokine-expressing cells reside within 
the CD3
þ cell fraction. It should be remembered that cytokine responses induced by polyclonal stimuli may overestimate T-cell contribution because under physiological conditions few of these tissue-trafficking T cells would be encountering their relevant antigen, so would unlikely be triggered to produce cytokine. By contrast, despite their numeric inferiority to T cells, mucosal ILC are likely to be activated directly by cytokine signals abundant in chronically inflamed tissue, such as IL6. IL6-induced stimulation of ILC effector function may prove to be especially pertinent in UC because IL23, the canonical ILC-activating cytokine, is produced at low levels in UC in comparison with CD. 32 In this study, IL6 neutralization reduced innate production of IL17A in TRUC mice and significantly attenuated disease severity, although the magnitude of impact was less than seen with ILC depletion or IL23 blockade. 7 This is in keeping with our observation that although IL6 is required for optimal activation of ILC effector function, other proximal cytokine signals, including IL23 and/or IL1 stimulation, additionally are required. IL6 blockade had a minimal impact on the intestinal microbiota, other than a minor shift in the proportional abundance of Firmicutes and a tendency for increased intestinal bacterial diversity. It is possible that this latter change occurred secondary to reduced intestinal inflammation in anti-IL6-treated mice. Indeed, IBD activity/ severity is recognized to correlate inversely with bacterial diversity in the gut. 33, 34 Our data support extending biological therapies targeting IL6 in IBD. The IL6R blocking antibody tocilizumab is efficacious in other inflammatory diseases, including arthritis 35, 36 and lupus, 37 and a pilot study in CD showed promising initial results. 38 In this study mucosal IL6 production was highly variable, however, only half of IBD patients produced more IL6 than non-IBD control patients. Similarly, the frequency of CD3 -IL7R þ cells, and the magnitude of IL6-induced cytokine responses by these cells also markedly was variable. With the promise of personalized medicine on the horizon, 39 it is tempting to speculate that treatment strategies targeting IL6 might be favored in patient subsets defined by high mucosal expression of IL6 and/or high frequencies of IL6 responsive effector cells in diseased tissue.
In summary, we have shown that IL6 augments pathogenic cytokine production by intestinal ILCs in chronic intestinal inflammation and that this pathway may be operational in human IBD. Novel therapeutic strategies targeting ILC or their proximal cytokine signals may offer a new treatment paradigm in IBD.
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Supplementary Materials and Methods
Microbiota Analysis
DNA was extracted from mouse fecal samples using the FastDNA SPIN Kit for Soil and a FastPrep 24 machine (MP Biomedicals Santa Ana, CA) according to the protocol provided by the manufacturer. Bacterial 16S ribosomal RNA genes were PCR-amplified using barcoded primers MiSeq 27F (5'AAT GATACGGCGACCACCGAGATCTACACTATGGTAATTCCAGMGT TYGATYMTGGCTCAG-3') and MiSeq-338R (5'-CAAGCAGAA GACGGCATACGAGAT-barcode-AGTCAGTCAGAAGCTGCCTCCC GTAGGAGT-3'), which target variable regions V1-V2 of the 16S ribosomal RNA gene. Q5 Taq polymerase (New England Biolabs, Ipswich, MA) was used for the PCR step, and 4 PCR reactions were performed per sample. Cycling conditions were as follows: 98 C for 2 minutes, followed by 20 cycles of 98 C for 30 seconds, 50 C for 30 seconds, 72 C for 90 seconds, and then a final extension step at 72 C for 5 minutes. The 4 PCR reactions from each DNA extraction then were pooled and concentrated down to 25 mL volumes per sample. PCR amplicons then were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Ltd, Carlsbad, CA) and equimolar concentrations of each were added to a final mastermix for sequencing, using an Illumina MiSeq (San Diego, CA) machine with 2 Â 250 bp read length. Sequence data have been deposited in the European Nucleotide Archive under Study Accession Number ERP005850 and Sample Accession numbers ERS459682-ERS459702.
The sequence data were processed by following the MiSeq SOP of the mothur software package (Available at: http://www.mothur.org/wiki/MiSeq_SOP). 1 Paired-read contigs were created from the forward and reverse read sequence data, and preliminary quality processing was performed by removing all contigs that were shorter than 260 bp, longer than 450 bp, or those that contained any ambiguous bases or homopolymeric stretches longer than 7 bases. Perseus, 2 as implemented in mothur, was used to remove putative chimeras, and any reads mapping to chloroplasts, mitochondria, eukarya, or archaea also were removed. After these steps, more than 486,000 sequences were left in the final data set (range, 447-51,571 sequences per sample). Next, after a preclustering step (diffs, 3), 97% similarity OTUs were generated. Taxonomic classifications for each of these OTUs were created using the RDP taxonomy provided at the mothur web page. Metastats, 3 as implemented in mothur, was used to test for significant differences in the proportional abundance of each of the phyla present, and the 150 most abundant OTUs between anti-IL6 and control mice. Bacterial diversity was measured by generating Shannon and inverse Simpson indices in mothur. Before these calculations each sample was subsampled randomly down to 447 reads to ensure equal sequencing depth for each. Kruskall-Wallis and MannWhitney U tests, implemented in Minitab v16, were used to test for significant differences in diversity measures between the anti-IL6 and control mouse groups. A cluster dendrogram, using the Bray Curtis calculator, also was generated in mothur from the subsampled data set, and subsequently was visualized using the iTOL online software resource. 
